受强制性开放获取政策约束的文章 - Jeffrey Breall了解详情
无法在其他位置公开访问的文章：2 篇
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study
RP Kreutz, EJ Stanek, R Aubert, J Yao, JA Breall, Z Desta, TC Skaar, ...
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30 (8 …, 2010
强制性开放获取政策： US National Institutes of Health
Biochemical characterisation of amyloid by endomyocardial biopsy
MD Benson, J Breall, OW Cummings, JJ Liepnieks
Amyloid 16 (1), 9-14, 2009
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：10 篇
Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial
ES Brilakis, R Edson, DL Bhatt, S Goldman, DR Holmes, SV Rao, ...
The Lancet 391 (10134), 1997-2007, 2018
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention
M Vaduganathan, RA Harrington, GW Stone, EN Deliargyris, PG Steg, ...
Journal of the American College of Cardiology 69 (2), 176-185, 2017
强制性开放获取政策： US National Institutes of Health
C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting
RP Kreutz, J Owens, JA Breall, D Lu, E von der Lohe, I Bolad, A Sinha, ...
Blood Coagulation & Fibrinolysis 24 (3), 321-326, 2013
强制性开放获取政策： US National Institutes of Health
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
RP Kreutz, P Nystrom, Y Kreutz, J Miao, Z Desta, JA Breall, L Li, ...
Clinical Pharmacology: Advances and Applications, 13-20, 2012
强制性开放获取政策： US National Institutes of Health
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease
RP Kreutz, A Bitar, J Owens, Z Desta, JA Breall, E von der Lohe, A Sinha, ...
Journal of thrombosis and thrombolysis 38, 380-387, 2014
强制性开放获取政策： US National Institutes of Health
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
RP Kreutz, J Owens, Y Jin, P Nystrom, Z Desta, Y Kreutz, JA Breall, L Li, ...
Clinical pharmacology: advances and applications, 185-192, 2013
强制性开放获取政策： US National Institutes of Health
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response
RP Kreutz, JA Breall, Y Kreutz, J Owens, D Lu, I Bolad, E von der Lohe, ...
Thrombosis research 130 (2), 198-202, 2012
强制性开放获取政策： US National Institutes of Health
Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention
RP Kreutz, G Schmeisser, B Maatman, A Schaffter, A Sinha, ...
Thrombosis and haemostasis 117 (02), 426-428, 2017
强制性开放获取政策： US National Institutes of Health
Prediction of ischemic events after percutaneous coronary intervention: thrombelastography profiles and factor XIIIa activity
RP Kreutz, G Schmeisser, A Schaffter, S Kanuri, J Owens, B Maatman, ...
TH Open 2 (02), e173-e181, 2018
强制性开放获取政策： US National Institutes of Health
Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
RP Kreutz, JA Breall, A Sinha, E von der Lohe, RJ Kovacs, DA Flockhart
Clinical pharmacology: advances and applications, 45-50, 2016
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定